VINEETLABVineet Laboratories Limited
Chemicals · Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VINEETLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Risk gate: safety score is only 24/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • ROE: 3.7%
- • ROCE: -34.3%
- • MACD: bearish
- • Price vs EMA21: below
Bull case
- • Revenue growth: 22.6% YoY
- • Profit growth: 105.5% YoY
- • PEG ratio: 0.35
- • Price vs SMA200: above
Bear case
- • ROE: 3.7%
- • ROCE: -34.3%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROE: 3.7%
- • ROCE: -34.3%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹2.05). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.